Syndax Pharmaceuticals, Inc
Insiders
Last 12 monthsSales planned on beside the trades reported on , and whether each names a .
Planned ·
$2,709,203
9 notices · 135,977 sh
Oct 2025 to Oct 2026
Reported ·
$1,964,351
8 sales · 0 buys
Oct 2025 to Jun 2026
The two figures cover different periods.
2 of 8 reported sales carry the 10b5-1 box. Together they are 0.12% of the shares on issue.
under a no plan named▼ salesize is dollars
Form 144 notices, newest first
2026-07-08MICHAEL METZGER, Chief Executive Officer$752,395
2026-06-12Botwood Nicholas A.J., Head of R&D, CMO$566,693
2026-06-11Botwood Nicholas A.J., Head of R&D, CMO$609,435
Form 4, 2026-06-12: sold 65,515 at $18.07 Form 4 ↗
2026-06-01Goldan Keith A., Chief Financial Officer$22,352
Form 4, 2026-06-02: sold 1,177 at $18.99 Form 4 ↗
2026-06-01Metzger Michael A, Chief Executive Officer$130,028
Form 4, 2026-06-02: sold 6,847 at $18.99 Form 4 ↗
2026-02-09Metzger Michael A, Chief Executive Officer$360,826
Form 4, 2026-02-10: sold 17,159 at $21.03 Form 4 ↗
2026-02-09Goldan Keith A., Chief Financial Officer$71,707
Form 4, 2026-02-10: sold 3,410 at $21.03 Form 4 ↗
2026-02-06Metzger Michael A, Chief Executive Officer$152,836
Form 4, 2026-02-06: sold 7,412 at $20.62 Form 4 ↗